Trial Profile

Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active RA. A Multicenter Post-Marketing Observational Study in Routine Clinical Use.

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 24 Jan 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Dec 2011 Actual patient number changed from 84 to 82 as reported by ClinicalTrials.gov.
21 Mar 2011 Actual initiation date changed from Mar 2008 to Apr 2008 as reported by ClinicalTrials.gov.
21 Mar 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com